Share chart Bristol-Myers
Extended chart
Simple chart
About Bristol-Myers
Компания Bristol-Myers Squibb обнаруживает, разрабатывает, лицензирует, производит и продает биофармацевтические продукты по всему миру. Компания предлагает продукцию в терапевтических классах гематологии, онкологии, сердечно-сосудистой системы и иммунологии. more detailsIPO date | 1972-01-01 |
---|---|
ISIN | US1101221083 |
Industry | Pharmaceuticals |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 4.75 |
Дивиденд ао | 0.62 |
Сайт | http://www.bms.com |
Цена ао | 51.34 |
Change price per day: | 0% (51.34) |
---|---|
Change price per week: | -3.26% (53.07) |
Change price per month: | -13% (59.01) |
Change price per 3 month: | -7.89% (55.74) |
Change price per half year: | -3.8% (53.37) |
Change price per year: | +5.83% (48.51) |
Change price per 3 year: | -32.56% (76.13) |
Change price per 5 year: | -22.24% (66.02) |
Change price per 10 year: | -32.16% (75.68) |
Change price per year to date: | -10.84% (57.58) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
1.05% | 0.62 | I кв. 2025 | 02.04.2025 | 04.04.2025 | 21.04.2025 |
1.07% | 0.62 | IV кв. 2024 | 01.01.2025 | 03.01.2025 | 20.01.2025 |
1.17% | 0.6 | III кв. 2024 | 02.10.2024 | 04.10.2024 | 21.10.2024 |
1.26% | 0.6 | II кв. 2024 | 03.07.2024 | 05.07.2024 | 22.07.2024 |
1.45% | 0.6 | I кв. 2024 | 02.04.2024 | 04.04.2024 | 19.04.2024 |
1.16% | 0.6 | IV кв. 2023 | 02.01.2024 | 04.01.2024 | 19.01.2024 |
0.98% | 0.57 | III кв. 2023 | 03.10.2023 | 05.10.2023 | 20.10.2023 |
0.89% | 0.57 | II кв. 2023 | 04.07.2023 | 06.07.2023 | 21.07.2023 |
0.85% | 0.57 | I кв. 2023 | 04.04.2023 | 06.04.2023 | 21.04.2023 |
0.79% | 0.57 | IV кв. 2022 | 03.01.2023 | 05.01.2023 | 20.01.2023 |
Institutions | Volume | Share, % |
---|---|---|
Vanguard Group Inc | 198159772 | 9.78 |
Blackrock Inc. | 168103766 | 8.29 |
JP Morgan Chase & Company | 90048274 | 4.44 |
State Street Corporation | 89446206 | 4.41 |
Capital International Investors | 61528492 | 3.04 |
FMR, LLC | 42612466 | 2.1 |
Geode Capital Management, LLC | 39677105 | 1.96 |
Norges Bank Investment Management | 30413639 | 1.5 |
Morgan Stanley | 29381471 | 1.45 |
Ameriprise Financial, Inc. | 27744111 | 1.37 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
iShares Evolved U.S. Innovative Healthcare ETF | 5.33 | 0.000586 | 2.79 |
John Hancock Multifactor Healthcare ETF | 3.07 | 29.34 | 1.62 |
Global X Longevity Thematic ETF | 2.56 | 4.72 | 0.36 |
AVDR U.S. LargeCap ESG ETF | 2.42 | 0 | |
US Equity Dividend Select ETF | 2.02849 | -2.35 | 3.20163 |
Donoghue Forlines Innovation ETF | 1.84178 | 10.06 | 0.89556 |
UVA Dividend Value ETF | 1.65 | 0 | 3.23 |
IQ Engender Equality ETF | 1.43909 | 30.64 | 1.74017 |
FCF US Quality ETF | 1.43627 | 18.99 | 1.58997 |
Fidelity New Millennium ETF | 1.31841 | -2.96 | 1.58241 |
Pacer Salt Low truBeta US Market ETF | 1.16 | 20.77 | 2.09 |
iShares Morningstar Large-Cap Value ETF | 0.38783 | 63.82 | 2.17567 |
iShares Morningstar Large-Cap ETF | 0.2001 | 257.57 | 1.41244 |
Columbia U.S. ESG Equity Income ETF | 0.17609 | -99.18 | 1.44131 |
JPMorgan Corporate Bond Research Enhanced ETF | 0.07 | 6.26 | 4.16 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Timothy Power | VP & Head of Investor Relations | N/A | |
Mr. Greg Meyers | Executive VP and Chief Digital & Technology Officer | N/A | 1973 (52 years) |
Ms. Kimberly M. Jablonski | Chief Compliance & Ethics Officer | N/A | |
Ms. Ahn Amanda Poole | Executive Vice President & Chief Human Resources Officer | N/A | 1975 (50 years) |
Dr. Christopher S. Boerner Ph.D. | CEO & Chairman | 1971 (54 years) | |
Mr. David V. Elkins | Executive VP & CFO | 1968 (57 years) | |
Ms. Sandra Leung Esq. | Executive VP & General Counsel | 1961 (64 years) | |
Mr. Samit Hirawat M.D. | Executive VP, Chief Medical Officer & Head of Development | 1969 (56 years) | |
Dr. Joseph J. Eiden Jr. | Head of Medical Affairs | 1949 (76 years) | |
Mr. Adam Lenkowsky | Executive VP, Chief Commercialization Officer & Head of U.S. Oncology | 1972 (53 years) |
Address: United States, New York, 430 East 29th Street - open in Google maps, open in Yandex maps
Website: http://www.bms.com
Website: http://www.bms.com